Institut Jules Bordet — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

6 Recruiting

4 Completed trials

3 Countries active

42 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 2 Phase II: 8 Phase I/II: 1

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Rectal cancer stage III 2 Rectal cancer stage II 2 HER2 positive breast cancer 2 Androgen deficiency 1 Hormone receptor positive breast cancer 1 Breast conserving surgery 1 Palliative care 1 Triple negative breast cancer 1 Breast cancer recurrent 1 Invasive breast carcinoma 1

Top IMPs

OLECLUMAB 2 TRASTUZUMAB 2 TRASTUZUMAB CONJUGATED TO N-SUCCINYLDESFERRIOXAMINE B-TETRAFLUORPHENOL AND RADIOLABELED WITH ZIRCONIUM (89ZR) 2 CARBOPLATIN 1 DOXORUBICIN HYDROCHLORIDE 1 DURVALUMAB 1 NIVOLUMAB 1 PACLITAXEL 1 PACLITAXEL ALBUMIN-BOUND 1 REGORAFENIB 1 TESTOSTERONE DECANOATE, TESTOSTERONE ISOCAPROATE, TESTOSTERONE PHENYLPROPIONATE, TESTOSTERONE PROPIONATE 1

All trials

11 total

HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Not authorised

2024-516253-49-00 Phase II 1 country TRASTUZUMAB; TRASTUZUMAB CONJUGATED TO N-SUCCINYLDESFERRIOXAMINE B-TETRAFLUORPHE…
Testosterone intake in supportive care patients: impact on quality of life. Recruiting

2025-522023-10-00 Phase II 1 country TESTOSTERONE DECANOATE, TESTOSTERONE ISOCAPROATE, TESTOSTERONE PHENYLPROPIONATE,…
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Recruiting

2024-516253-49-01 Phase II 2 countries TRASTUZUMAB; TRASTUZUMAB CONJUGATED TO N-SUCCINYLDESFERRIOXAMINE B-TETRAFLUORPHE…
Unravelling the local and systemic effects of primary surgery and perioperative use of ketorolac and pregabalin in primary breast cancer pat… Recruiting

2023-507440-36-00 Phase II 1 country
ICG-fluorescence imaging for intraoperative breast cancer margins evaluation: a dose-timing study Recruiting

2023-504024-26-00 Phase II 1 country
Efficacy and safety of conventional neoadjuvant therapy versus total neoadjuvant therapy in older patients with locally advanced rectal canc… Recruiting

2023-506703-26-00 Phase III 1 country
Immunological variables associated to ICI toxicity in cancer patients Recruiting

2023-505360-11-00 Phase II 1 country CARBOPLATIN; PACLITAXEL ALBUMIN-BOUND
A phase II trial of neoadjuvant REGorafenib in combination with nIvolumab and short-course radiotherapy iN intermediate-risk, stage II-III r… Ended

2024-516554-22-00 Phase II 1 country NIVOLUMAB; REGORAFENIB
Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy … Ended

2023-506258-19-00 Phase III 1 country
Neo-adjuvant chemotherapy combined with Stereotactic Body Radiotherapy to the primary tumour +/- durvalumab (MEDI4736), +/- oleclumab (MEDI9… Ended

2024-511849-19-00 Phase II 2 countries DOXORUBICIN HYDROCHLORIDE; OLECLUMAB; PACLITAXEL
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Lo… Ended

2024-511850-34-00 Phase I/II 2 countries DURVALUMAB; OLECLUMAB

Showing 1–11 of 11 trials

← All sponsors A–Z